Business, energy, technology, markets and global industry news from Business News Today

weight management

PharmaDeviceNews weight management
Pharma & Biotech

Evidation GLP-1 study reveals major growth runway but exposes widening access gaps

Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.

Read More
Representative image: Genentech’s obesity drug data update at ADA 2026 underscores rising interest in enicepatide, petrelintide and next-generation weight management therapies.
Pharma & Biotech

Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?

Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.

Read More
Representative image of berberine-infused natural GLP-1 supplements with botanical ingredients and healthy food cues, reflecting PureHealth Research’s push into metabolic wellness, satiety support, and the fast-growing consumer health market for natural GLP-1 alternatives.
Pharma & Biotech

Why PureHealth Research’s berberine GLP-1 supplement push enters a crowded evidence debate

GLP-1 demand is reshaping supplements. PureHealth Research’s berberine launch tests where wellness claims meet evidence and regulation.

Read More
Representative image: Novo Nordisk’s Wegovy pill launch in the U.S. obesity drug market is illustrated through unbranded tablets, prescription growth data and healthcare market signals, reflecting rising demand for oral GLP-1 weight-loss treatments.
Pharma & Biotech

Can Novo Nordisk’s Wegovy pill reshape the obesity market before Eli Lilly catches up?

Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.

Read More
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected

Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.

Read More
Zepbound KwikPen arrives on Ro as Eli Lilly tightens control over obesity drug distribution
Medical Devices & Diagnostics

Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing

Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.

Read More
Representative image illustrating injectable obesity drug research, reflecting the competitive landscape highlighted by Novo Nordisk’s CagriSema trial results and ongoing comparisons with tirzepatide in next-generation weight-loss therapies.
Pharma & Biotech

Novo Nordisk’s CagriSema misses non-inferiority against tirzepatide: Why a 23% weight loss still reshapes the obesity pipeline

Novo Nordisk A/S disclosed headline Phase 3 data from the REDEFINE 4 trial showing that CagriSema, its fixed-dose combination of cagrilintide and semaglutide, achieved 23 percent weight loss over 84 weeks in people with obesity but failed to meet the primary endpoint of non-inferiority versus tirzepatide. The open-label head-to-head study compared once-weekly CagriSema 2.4 mg/2.4

Read More
Pharma & Biotech

Brello Rise enters the obesity care landscape as a digital wellness adjunct to medical weight loss

Brello Health launches Brello Rise, a digital studio for patients in medical weight loss programs. Find out what this signals for obesity care models.

Read More